RALLYBIO CORPORATION Net Fee Amt
RALLYBIO CORPORATION (RLYB) had Net Fee Amt of $0.08 as of 2026-08-26, per its S-4/A filed 2026-08-26.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-26
- 2026-08-26: Net Fee Amt $0.08.
- 2026-07-15: Net Fee Amt $0.91.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-26 | $0.08 S-4/A · filed 2026-08-26 |
| 2026-07-15 | $0.91 S-4 · filed 2026-07-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |